Human PD-1hiCD8+ T Cells Are a Cellular Source of IL-21 in Rheumatoid Arthritis

Background Rheumatoid arthritis (RA) is a prototypical autoantibody-driven autoimmune disease in which T-B interactions play a critical role. Recent comprehensive analysis suggests that PD-1(+)CD8(+) T cells as well as two distinct IL-21-producing PD-1(+)CD4(+) T cell subsets, follicular helper T (Tfh) and peripheral helper T (Tph) cells, are involved in the pathogenesis of RA. Herein, we aimed to clarify a generation mechanism of IL-21-producing CD8(+) T cells in humans, and to characterize this novel subset in patients with RA. Methods CD8(+) T cells in the peripheral blood (PB) and synovial fluid (SF) of healthy control (HC) and patients with RA were subject to the analysis of IL-21 mRNA and protein. We evaluated the surface marker, cytokine and transcription profiles of IL-21-producing CD8(+) T cells in HCPB, RAPB and RASF. Results IL-21-producing CD8(+) T cells were enriched in the CD45RA(-)(memory) PD-1(+), especially PD-1(hi) subpopulation, and IL-12 and IL-21 synergistically induced IL-21 production by naive CD8(+) T cells. Memory PD-1(hi)CD8(+) T cells in HCPB facilitated plasmablast differentiation and IgG production in an IL-21-dependent manner. In addition, PD-1(hi)CD8(+) T cells in RASF and RAPB produced large amounts of IL-21 and were characterized by high levels of CD28, ICOS, CD69, HLA-DR, and CCR2 but not CXCR5. Furthermore, PD-1(hi)CD8(+) T cells expressed high levels of transcripts of MAF and PRDM1, a feature observed in Tph cells. Conclusions Identification of IL-21-producing PD-1(hi)CD8(+) T cells expands our knowledge of T cell subsets with B helper functions in RA. Selective targeting of these subsets could pave an avenue for the development of novel treatment strategies for this disease.

Automated summary

The identification of IL-21-producing PD-1(hi)CD8(+) T cells in patients with RA expands understanding of T cell subsets with B helper functions in the disease. Selective targeting of these subsets could lead to the development of novel treatment strategies for RA.